Citadel Advisors
NVCT icon

Citadel Advisors’s Nuvectis Pharma NVCT Stock Holding History

Citadel Advisors’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Buy
115,532
+37,107
+47% +$415K ﹤0.01% 6417
2026
Q1 		$606K Buy
+78,425
New +$672K ﹤0.01% 8828
2025
Q2 		– Sell
-10,344
Closed -$93.8K – 14265
2025
Q1 		$101K Buy
+10,344
New +$74.5K ﹤0.01% 11445
2024
Q3 		– Sell
-14,937
Closed -$94.6K – 14919
2024
Q2 		$94.6K Buy
+14,937
New +$102K ﹤0.01% 10996
2023
Q3 		– Sell
-28,028
Closed -$448K – 14829
2023
Q2 		$448K Buy
+28,028
New +$447K ﹤0.01% 8189
2022
Q3 		– Sell
-35,069
Closed -$393K – 13288
2022
Q2 		$393K Buy
+35,069
New +$434K ﹤0.01% 9175

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Citadel Advisors's NVCT Position: Q2 2026 in Review

Citadel Advisors increased its Nuvectis Pharma (NVCT) stake by 47% in Q2 2026, buying an estimated $415K and bringing the position to 115,532 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #6417.

Citadel Advisors first reported a position in NVCT in Q2 2022 and has held it in 6 quarters since. 82 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Citadel Advisors held 115,532 shares of Nuvectis Pharma worth $2.12M as of Q2 2026.
  • Citadel Advisors bought 37,107 Nuvectis Pharma shares in Q2 2026, an estimated $415K.
  • Nuvectis Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6417 holding.
  • Citadel Advisors first reported a position in Nuvectis Pharma in Q2 2022 and has held it in 6 quarters since.
  • 82 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.